10th DIA Asia New Drug Conference in Japan

With the accelerated globalization of drug development in recent years, the importance of clinical development utilizing multi regional clinical trials (MRCT) especially in east Asian region is increasing mainly because of the higher similarity of ethnic factors within the region. Under such circumstances, Case of new drugs approved based on the results of MRCT in east Asian region are accumulating. In addition, since the postmarketing safety measures including the maintenance of labeling required by the regulatory agency varies in each region, Marketing Authorization Holders have to deal with each local regulations. In this session, experts from each regulatory agency will introduce the recent regulatory issues about drug development and safety measures in each region. Furthermore, topics regarding the new framework which some regulatory agencies have started to facilitate innovative drug development will be also introduced. It is expected to be helpful for drug development and fostering in east Asian region by understanding and utilizing the updated regulatory information.